Amneal Pharmaceuticals, Inc. AMRX Operating Income
Operating Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s operating income?
- Amneal Pharmaceuticals, Inc. (AMRX) reported operating income of $141.77M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s operating income changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s operating income increased by 41.3% year-over-year, from $100.35M to $141.77M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s operating income?
- Over 3 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s operating income has grown at a 37.2% compound annual growth rate (CAGR), from $152.72M to $394.1M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.